The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma
A Srivastava, SK Doppalapudi, HV Patel… - Current opinion in …, 2022 - journals.lww.com
The 2020s utilize the molecular profiling of advanced RCC as a scaffold for recent trials in
immunotherapy and targeted therapies. Going forward, emphasizing patient-reported …
immunotherapy and targeted therapies. Going forward, emphasizing patient-reported …
Hot topics in renal cancer pathology: implications for clinical management
ABSTRACT Introduction The updated European Association of Urology (EAU) Guidelines
issued a weak recommendation for adjuvant pembrolizumab for patients with high-risk …
issued a weak recommendation for adjuvant pembrolizumab for patients with high-risk …
Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy
B Shen, F Luo, N Yuan, J Yin, Y Chai, L Sun… - Open …, 2024 - degruyter.com
Objectives The management of patients undergoing bilateral nephrectomy for renal cancer
presents significant challenges, particularly in addressing hypotension, anemia, and tumor …
presents significant challenges, particularly in addressing hypotension, anemia, and tumor …
Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma
JK Rudzinski, BB Beech, B Wang, G Sonpavde… - A Guide to Management …, 2023 - Springer
High-grade/stage clinically localized renal cell carcinoma (RCC) is associated with a
significant risk of recurrence following definitive surgical therapy. Various models have been …
significant risk of recurrence following definitive surgical therapy. Various models have been …
[引用][C] Adjuvant Pembrolizumab After Nephrectomy for Renal Cell Carcinoma
D Ambinder - WHY IS PRECISION MEDICINE COMPLICATED IN …